Literature DB >> 6673378

Metabolism and excretion of butein, 2',3,4-trihydroxychalcone, 3-O-methylbutein, 4-O-methylbutein and 2',4',4-trihydroxychalcone in the rat.

S Brown, L A Griffiths.   

Abstract

Butein (2',3,4,4'-tetrahydroxychalcone) and 2',3,4-trihydroxychalcone, following administration to bile-duct-cannulated rats, gave rise to the corresponding 3-O-methyl ethers which were excreted in conjugated forms in bile and urine. After parenteral and oral administration of [14C]butein, 53% and 20% of the dose, respectively, was excreted in bile in 24h. After oral administration of [14C]butein, 4-O-methylbutein, or 2',4',4-trihydroxychalcone to non-cannulated rats, 51%, 58% and 40% dose, respectively, was excreted in faeces, and 39%, 37% and 56%, respectively, in urine. Intraperitoneal administration of butein to non-cannulated rats led to excretion of 41% dose in urine and 56% in faeces. 3-O-Methylbutein and 4-O-methylbutein were demethylated in vivo and on incubation with rat-intestinal microflora in vitro, whilst 2',4-dihydroxy-3-methoxychalcone and 2',3-dihydroxy-4-methoxychalcone were not demethylated in vivo or in vitro. Following parenteral and oral administration of 4-O-methylbutein to bile-duct-cannulated rats, 91% and 21% dose, respectively, was excreted in the bile in 24h. After parenteral or oral administration of 2',4',4-trihydroxychalcone to cannulated rats, approx. 100% and 45% dose, respectively, was excreted in the bile in 24h. Trace amounts of 2',4',4-trihydroxychalcone were hydroxylated to give butein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6673378     DOI: 10.3109/00498258309052228

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Evaluation of potential antidepressant-like activity of chalcone-1203 in various murine experimental depressant models.

Authors:  Li-Ping Guan; Li-Ming Tang; Cheng-Yan Pan; Shui-Lian Zhao; Si-Hong Wang
Journal:  Neurochem Res       Date:  2013-12-17       Impact factor: 3.996

Review 2.  Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19.

Authors:  Ashis K Mukherjee; Dhruba J Chattopadhyay
Journal:  Phytother Res       Date:  2022-02-11       Impact factor: 6.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.